Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Approves Pemigatinib for FGFR2+ Cholangiocarcinoma

April 18th 2020

The FDA has approved pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.

FDA Grants Surufatinib Fast Track Status in pNETS and Other Neuroendocrine Tumors

April 18th 2020

The FDA has granted Fast Track Designations to surufatinib for the treatment of advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors in patients who are not amenable for surgery.

Dr. Bekaii-Saab on the Need for Umbrella Trials in Biliary Tract Cancer

April 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Dr. Parikh on Determining Transplant Eligibility in HCC

April 17th 2020

Neehar Parikh, MD, discusses criteria for determining transplant eligibility in hepatocellular carcinoma.

Dr. Choti on the Role of Upfront Surgery in Pancreatic Adenocarcinoma

April 17th 2020

Michael A. Choti, MD, discusses the role of upfront surgery in pancreatic adenocarcinoma.

PROs Provide Insight On Atezolizumab/Bevacizumab Benefit in HCC

April 16th 2020

Peter R. Galle, MD, PhD, discusses the PROs analysis from the IMbrave150 trial in HCC and the importance of understanding patient experience during treatment.

Pemigatinib Pivotal Cholangiocarcinoma Data Published as FDA Weighs Approval

April 16th 2020

Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.

Dr. Shah on Optimal Sequencing in Gastroesophageal Cancer

April 15th 2020

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Multidisciplinary Care to Provide Best Possible Outcomes in HCC

April 15th 2020

Amit Singal, MD, MS, discussess optimal models for multidisciplinary care in hepatocellular carcinoma in light of the practice-changing IMbrave150 trial.

Dr. Janjigian on the JAVELIN Gastric 100 Study With Avelumab in Gastric/GEJ Cancer

April 14th 2020

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Dr. O'Reilly on the Potential Role of Veliparib in Pancreatic Cancer

April 14th 2020

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

Dr. Ilson on the Utility of Zolbetuximab in Claudin-Positive Gastric Cancers

April 14th 2020

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

Dr. Salem on the Role of Locoregional Therapy in HCC

April 14th 2020

Riad Salem, MD, discusses the role of locoregional therapy in hepatocellular carcinoma.

Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic Cancer

April 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

Dr. Abou-Alfa on Sequencing Challenges in Metastatic HCC

April 11th 2020

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Dr. Chung on the Importance of Genomic Testing in Pancreatic Cancer

April 9th 2020

Vincent Chung, MD, discusses the importance of genomic testing in pancreatic cancer.

FDA Approves Encorafenib/Cetuximab Combo for BRAF+ mCRC

April 9th 2020

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

Dr. Sapisochin on the Benefits of Living Donor Transplant in HCC

April 8th 2020

Gonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.

Dr. O'Reilly on the Role of Germline Testing in Pancreatic Cancer

April 7th 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Talking HER2-Targeted Therapy With Dr. Marshall

April 7th 2020

We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer.